http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109745562-B

Outgoing Links

Predicate Object
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
filingDate 2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-109745562-B
titleOfInvention Application of ERK signal channel small molecule inhibitor in inhibiting chlamydia infection
abstract The invention discloses application of small molecule inhibitors VX-11e and BVD-523 in inhibiting chlamydia infection. The research of the invention finds that signal pathway inhibitors VX-11e and BVD-523 can obviously inhibit the infection of Chlamydia trachomatis, and compared with the reported MEK inhibitor U0126, the signal pathway inhibitors have obvious difference; the invention applies the micromolecule inhibitors VX-11e and BVD-523 to the chlamydia infection for the first time, and is expected to become a new drug for treating the chlamydia targeted host; meanwhile, the research also finds that the inhibitors VX-11e and BVD-523 have synergistic effect when being combined with azithromycin, and the VX-11e and BVD-523 can promote the anti-infection effect of the azithromycin after chlamydia infection, thereby having important application value for treating chlamydia infection. The invention has important significance for developing new medicaments for chlamydia trachomatis infection and searching new targets for assisting host treatment.
priorityDate 2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35051
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534456
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35050
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID813
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35049
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81071
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID813
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6197
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP51588
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID10566
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP70059
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419524263
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454031468
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP24664
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54684461
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP27638
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19799
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419581161
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447043
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11634725
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ59149
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35048
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35034
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP23916
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID60711
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00775
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83348
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426332378
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00764
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO97399
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID10566
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID60711
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6279
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00761

Total number of triples: 48.